An ongoing dialogue on HIV/AIDS, infectious diseases,
May 14th, 2010
The Luxury of the START Study … and Running Out of ART in Uganda
Over on our Journal Watch AIDS Clinical Care site, we did a poll asking about the ongoing START study:
In the START study, HIV-infected patients with CD4 counts greater than 500 cells per cubic mm are being randomized to start antiretroviral therapy right away or to wait until the CD4 count falls to 350 cells per cubic mm or below. If there were a START study site in your community, would you refer eligible patients to it?
87% said they would — which is interesting, since the study is having trouble enrolling, at least in some sites. If the study succeeds, we may learn definitively if treatment should be started at CD4 cell counts > 500, a longstanding debate in the field.
But the dilemma posed by the START study stands in sharp contrast to this life and death news about HIV treatment programs running out of money in Sub-Saharan Africa:
The global war on AIDS has racked up enormous successes over the past decade, most notably by providing drugs for millions of infected people in developing countries who would be doomed without this life-prolonging treatment. Now the campaign is faltering …
Although the number of Ugandans receiving drug treatments jumped from fewer than 10,000 a decade ago to nearly 200,000 today, hundreds of thousands more Ugandans need the drugs and likely can’t get them because clinics now routinely turn new patients away.
In the context of a limited supply of medications, the best approach to providing HIV treatment is to treat the sickest first — patients such as those described here in this NY Times article. But after the drugs run out, then what?
All of which goes to show that even the option of doing the START study is an incredible luxury, and that a person needing treatment for HIV is very very lucky to live here and not in Sub-Saharan Africa.
One Response to “The Luxury of the START Study … and Running Out of ART in Uganda”
Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
FROM NEJM — Recent Infectious Disease Articles- Borrelia burgdorferi Infection and Erythema Migrans January 15, 2026Expansion of the range of the lone star tick, a vector for southern tick-associated rash illness, has led to overlap with the range of the Lyme disease vector Ixodes scapularis, which may cause diagnostic uncertainty.
- Case 2-2026: A 63-Year-Old Man with Pulmonary Nodules, Liver Mass, and Vision Loss January 15, 2026A 63-year-old man was admitted to the hospital because of fever, cough, and vision loss in the right eye. He had pulmonary nodules, a liver mass, and multiple brain lesions. A diagnosis was made.
- Primary Palmoplantar Pustulosis January 15, 2026A 60-year-old man with a 30-pack-year smoking history presented with a 2-year history of a painful rash on his palms and soles. Numerous pustules with erosions, crusting, and surrounding erythema were noted.
- The Things We Carry January 15, 2026The ID, the pen, the epinephrine, the scalpel are the nonnegotiables, the necessities for any hospital shift. But they are not the only things a physician carries, and certainly not the most burdensome.
- Serogroup Switching in Neisseria meningitidis with Dual Antibiotic Resistance January 8, 2026Serogroup switching away from serogroup Y has been identified in the major ciprofloxacin-resistant Neisseria meningitidis strain, which may impede identification of ciprofloxacin-resistant cases of N. meningitidis infection.
- Borrelia burgdorferi Infection and Erythema Migrans January 15, 2026
An important point! The article in the NY times is chilling. Why does the medical community not learn? Yet, another vertical system – mother-infant health while ignoring the bigger picture? This is again only a bandaid on a much larger problem – we need health sector reform and overall strengthening! It is true that the international community should not are take governments out of their responsibility of providing adequate care for their people. But have we not bred that problem ourselves by going into countries and ignoring all local structures assuming they were corrupt anyway? Should we now, when interest is declining, make the convenient point of good governance at the expense of the poor and dis-enfranchised when for years we did not care as long as the government let us do whatever we wanted? When will the medical community learn that one problem cannot be taken out of context and that global health is not just medicine but needs to address all parts of society!